IL210841A - Preparations containing DNA dendrimers related to the sirna molecule, methods of preparation and their uses - Google Patents

Preparations containing DNA dendrimers related to the sirna molecule, methods of preparation and their uses

Info

Publication number
IL210841A
IL210841A IL210841A IL21084111A IL210841A IL 210841 A IL210841 A IL 210841A IL 210841 A IL210841 A IL 210841A IL 21084111 A IL21084111 A IL 21084111A IL 210841 A IL210841 A IL 210841A
Authority
IL
Israel
Prior art keywords
compositions
preparation
methods
sirna molecule
dna dendrimer
Prior art date
Application number
IL210841A
Other languages
English (en)
Hebrew (he)
Other versions
IL210841A0 (en
Original Assignee
Genisphere Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genisphere Llc filed Critical Genisphere Llc
Publication of IL210841A0 publication Critical patent/IL210841A0/en
Publication of IL210841A publication Critical patent/IL210841A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
IL210841A 2008-08-08 2011-01-24 Preparations containing DNA dendrimers related to the sirna molecule, methods of preparation and their uses IL210841A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18831808P 2008-08-08 2008-08-08
PCT/US2009/053264 WO2010017544A2 (en) 2008-08-08 2009-08-10 Long-acting dna dendrimers and methods thereof

Publications (2)

Publication Number Publication Date
IL210841A0 IL210841A0 (en) 2011-04-28
IL210841A true IL210841A (en) 2016-05-31

Family

ID=41664237

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210841A IL210841A (en) 2008-08-08 2011-01-24 Preparations containing DNA dendrimers related to the sirna molecule, methods of preparation and their uses

Country Status (7)

Country Link
US (1) US20120122800A1 (https=)
EP (2) EP2657342B1 (https=)
JP (1) JP5583667B2 (https=)
AU (1) AU2009279458B2 (https=)
CA (1) CA2731521C (https=)
IL (1) IL210841A (https=)
WO (1) WO2010017544A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206611A1 (en) 2010-02-24 2011-08-25 Genisphere, Llc DNA Dendrimers as Thermal Ablation Devices
US20140228234A1 (en) 2011-06-15 2014-08-14 Naomi B. Zak Target-recognition compositions comprising novel synthetic conjugates for trapping and diagnosis of a target molecule
CN103957997B (zh) * 2011-10-25 2018-09-21 奥麒个人护理产品公司 含有顺序发酵或同时发酵的提取物的组合物
US9651549B2 (en) * 2012-07-13 2017-05-16 Genisphere, Llc Lateral flow assays using DNA dendrimers
JP2016513089A (ja) * 2013-02-01 2016-05-12 ジェニスフィア・エルエルシー 細胞への遺伝子送達のための機能性ｄｎａデンドリマー
WO2014153394A1 (en) 2013-03-21 2014-09-25 Genisphere, Llc Cellular delivery of dna intercalating agents
CN107530439B (zh) * 2015-04-17 2021-06-18 詹尼斯费尔公司 用于治疗癌症的对人抗原R表达的siRNA抑制
WO2017143171A1 (en) * 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
IL260983B (en) * 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
JP7506601B2 (ja) 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ，インク． 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
EP3759225A1 (en) 2018-03-02 2021-01-06 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
JP7082659B2 (ja) * 2018-05-11 2022-06-08 中国塗料株式会社 防汚塗料組成物、防汚塗膜、防汚塗膜付き基材及び防汚方法
EP4022058A2 (en) 2019-08-30 2022-07-06 Sixfold Bioscience Ltd. Compositions for transfer of cargo to cells
PH12021553295A1 (en) * 2019-12-23 2022-08-01 Illumina Cambridge Ltd Nanoparticle with single site for template polynucleotide attachment
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
WO2021220053A2 (en) 2020-04-27 2021-11-04 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
KR20230035237A (ko) 2020-05-12 2023-03-13 일루미나, 인코포레이티드 재조합 말단 데옥시뉴클레오티딜 트랜스퍼라제를 사용하여 변형된 염기를 갖는 핵산의 생성
MX2023004104A (es) * 2020-10-09 2023-06-29 Sumitomo Pharma Co Ltd Conjugado de acido oligonucleico.
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
EP4703381A1 (en) 2024-09-03 2026-03-04 Institució Catalana de Recerca i Estudis Avançats Antibodies against icam-1 and applications thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5175270A (en) 1986-09-10 1992-12-29 Polyprobe, Inc. Reagents for detecting and assaying nucleic acid sequences
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6117631A (en) 1996-10-29 2000-09-12 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
EP1005573B1 (en) 1997-07-29 2006-05-24 Polyprobe, Inc. Dendritic nucleic acids exhibiting maximal self-assembly
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023248A1 (en) * 2001-12-07 2004-02-05 Whitehead Institiute For Biomedical Research Methods and reagents for improving nucleic acid detection
EP1530581A4 (en) * 2002-06-12 2006-08-30 Datascope Investment Corp POLYMERIC MARKING MOLECULES
US7223544B2 (en) * 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
US20100136614A1 (en) * 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
WO2008147526A1 (en) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference

Also Published As

Publication number Publication date
AU2009279458A1 (en) 2010-02-11
EP2320953B1 (en) 2015-07-15
JP5583667B2 (ja) 2014-09-03
CA2731521A1 (en) 2010-02-11
US20120122800A1 (en) 2012-05-17
CA2731521C (en) 2018-04-10
IL210841A0 (en) 2011-04-28
WO2010017544A2 (en) 2010-02-11
WO2010017544A3 (en) 2011-03-24
JP2011530537A (ja) 2011-12-22
EP2320953A2 (en) 2011-05-18
AU2009279458B2 (en) 2015-07-02
EP2657342A1 (en) 2013-10-30
EP2657342B1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
IL210841A (en) Preparations containing DNA dendrimers related to the sirna molecule, methods of preparation and their uses
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
SI2461833T1 (sl) Vakcinski sestavek, ki obsega 5'-cap modificirano RNA
ZA201007170B (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
IL208147A (en) Pleuvirus without replication, nucleic acid molecule, composition of pharmacy, its use and method of production
EP2294200A4 (en) NEW BIOSYNTHESIS GENES
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
EP2447253A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB0810518D0 (en) Improvements in or relating to manufacture of seats
IL208613A (en) Aztidine derivatives, methods of preparation, preparations containing them and their use
ZA201100960B (en) Improvements in or relating to compositions
PL2257583T3 (pl) Sposoby zwiększania wiązkości blend niemieszalnych polimerów
IL210992A0 (en) Improvements relating to nanodisperse compositions
EP2415869A4 (en) MODIFIED OLIGO-NUCLEIC ACID MOLECULE, PROCESS FOR PREPARATION AND USES THEREOF
EP2069485A4 (en) PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
GB0802754D0 (en) Antisense RNA targetting CXCR4
EP2320914A4 (en) CANCER COMPOSITION WITH microRNA MOLECULES
GB2471253B (en) Hairdye preparation composition
EP2285953A4 (en) RNA POLYPHOSPHATASE COMPOSITIONS, KITS AND THEIR USE
GB0815852D0 (en) Improvements relating to pharmaceutical compositions
SG10201602211PA (en) Modified Erythropoietin To Which Water-Soluble Long-Chain Molecule Is Added
EP2365956A4 (en) CURCUMIN COMPRISING SUSTAINED, PROLONGED NATURAL FUNCTIONAL GROUPS
IL207514A0 (en) Novel 7-subtituted derivatives of 3-carboxy-oxadiazino-quinolones, preparation thereof and use thereof as anti-bacterial agents
EP2358693A4 (en) PREPARATION OF DOCETAXEL

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed